Literature DB >> 1524964

Sodium valproate acutely inhibits lamotrigine metabolism.

A W Yuen1, G Land, B C Weatherley, A W Peck.   

Abstract

Concomitant administration of sodium valproate (VPA) reduced lamotrigine (LTG) total clearance by approximately 21% and increased elimination half-life and AUC. Reduced elimination occurred acutely within the first hour. Renal elimination of LTG was not impaired. The most probable explanation for this effect is hepatic competition between VPA and LTG for glucuronidation. Volume of distribution and parameters related to absorption, Cmax and tmax were unchanged.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1524964      PMCID： PMC1381438          DOI： 10.1111/j.1365-2125.1992.tb04079.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Mechanism of anticonvulsant action of valproate.

Authors:  A Chapman; P E Keane; B S Meldrum; J Simiand; J C Vernieres
Journal:  Prog Neurobiol       Date:  1982       Impact factor: 11.685

2.  Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine.

Authors:  M Depot; J R Powell; J A Messenheimer; G Cloutier; M J Dalton
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

3.  Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex.

Authors:  P de Miranda; S S Good; R Yarchoan; R V Thomas; M R Blum; C E Myers; S Broder
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

4.  A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures.

Authors:  P Loiseau; A W Yuen; B Duché; T Ménager; M C Arné-Bès
Journal:  Epilepsy Res       Date:  1990-11       Impact factor: 3.045

5.  A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy.

Authors:  J W Sander; P N Patsalos; J R Oxley; M J Hamilton; W C Yuen
Journal:  Epilepsy Res       Date:  1990-08       Impact factor: 3.045

6.  The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.

Authors:  S M Sim; D J Back; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans.

Authors:  A F Cohen; G S Land; D D Breimer; W C Yuen; C Winton; A W Peck
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

8.  The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome).

Authors:  J Posner; A F Cohen; G Land; C Winton; A W Peck
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

9.  Controlled trial of lamotrigine (Lamictal) for refractory partial seizures.

Authors:  S Jawad; A Richens; G Goodwin; W C Yuen
Journal:  Epilepsia       Date:  1989 May-Jun       Impact factor: 5.864

10.  Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats.

Authors:  A A Miller; P Wheatley; D A Sawyer; M G Baxter; B Roth
Journal:  Epilepsia       Date:  1986 Sep-Oct       Impact factor: 5.864
View more
  40 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Interstitial pneumonitis during lamotrigine therapy.

Authors:  Narayanamoorti Saravanan; Olayiwala Musibay Otaiku; Robert Namushi Namushi
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  Lamotrigine-induced rash: Can we stop worrying?

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

4.  A new generation of anticonvulsants for the treatment of epilepsy in children.

Authors:  O Carter Snead; Elizabeth J Donner
Journal:  Paediatr Child Health       Date:  2007-11       Impact factor: 2.253

5.  Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.

Authors:  A M Almeida; A C Falcão; F Sales; I Baldeiras; M J Rocha; M M Caramona
Journal:  Eur J Clin Pharmacol       Date:  2006-07-27       Impact factor: 2.953

6.  Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.

Authors:  R G Morris; A B Black; A L Harris; A B Batty; B C Sallustio
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

7.  Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.

Authors:  M Marchand; E Fuseau; D J Critchley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-02       Impact factor: 2.745

8.  Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients.

Authors:  Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 9.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

10.  Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.

Authors:  William R Garnett; Erik K St Louis; Thomas R Henry; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.